Oncotarget

Research Papers:

Therapeutic efficacy of tumor-targeting Salmonella typhimurium A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models

Takashi Murakami _, Yukihiko Hiroshima, Ming Zhao, Yong Zhang, Takashi Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo and Robert M. Hoffman

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31368-31377. https://doi.org/10.18632/oncotarget.5187

Metrics: PDF 857 views  |   HTML 983 views  |   ?  


Abstract

Takashi Murakami1,2,3, Yukihiko Hiroshima1,2,3, Ming Zhao1, Yong Zhang1, Takashi Chishima3, Kuniya Tanaka3, Michael Bouvet2, Itaru Endo3, Robert M. Hoffman1,2

1AntiCancer, Inc., San Diego, California, USA

2Department of Surgery, University of California San Diego, California, USA

3Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

Correspondence to:

Robert M. Hoffman, e-mail: all@anticancer.com

Keywords: nude mice, orthotopic, liver metastasis, red fluorescent protein, Salmonella typhimurium A1-R

Received: June 30, 2015     Accepted: August 25, 2015     Published: September 07, 2015

ABSTRACT

Liver metastasis is the most frequent cause of death from colon and other cancers. Generally, liver metastasis is recalcitrant to treatment. The aim of this study is to determine the efficacy of tumor-targeting Salmonella typhimurium A1-R on liver metastasis in orthotopic mouse models. HT-29 human colon cancer cells expressing red fluorescent protein (RFP) were used in the present study. S. typhimurium A1-R infected HT-29 cells in a time-dependent manner, inhibiting cancer-cell proliferation in vitro. S. typhimurium A1-R promoted tumor necrosis and inhibited tumor growth in a subcutaneous tumor mouse model of HT-29-RFP. In orthotopic mouse models, S. typhimurium A1-R targeted liver metastases and significantly reduced their growth. The results of this study demonstrate the future clinical potential of S. typhimurium A1-R targeting of liver metastasis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5187